LONDON (AP) – The University of Oxford announced saturday that it will resume a trial for a coronavirus vaccine to be presented with pharmaceutical company AstraZeneca, a resolution that occurs days after the examination was discontinued following an informed side effect on a British patient.
In a statement, the university showed a reboot at all of its test sites in the UK after regulators gave the go-ahead after Sunday’s break.
“The indefinite review procedure has come to an end and following the recommendations of the indefinite protection review committee and the British regulator, MHRA, trials will resume in the UK,” he said.
The vaccine being developed through Oxford and AstraZeneca is widely known as one of the leading applicants among dozens of test-stage coronavirus vaccines worldwide.
UK Health Secretary Matt Hancock welcomed the reboot and said in a tweet it was “good news for everyone” that the essay would “be operational again. “
The university said that in giant trials like this, “some participants are expected to become ill and that each case will have to be thoroughly evaluated to ensure a full protection assessment.
He said about 18,000 international people have won his vaccine so far. Volunteers from some of the most affected countries (Britain, Brazil, South Africa and the United States) are participating in the trial.
Brazilian fitness regulator Anvisa announced saturday that he had approved the resumption of the “Oxford vaccine” in the South American country after receiving official data from AstraZeneca.
Although Oxford discloses data on the patient’s disease due to the confidentiality of the participants, an AstraZeneca spokesperson said this week that a woman had developed severe neurological symptoms that caused the break. inflammation of the spinal cord.
The university presses that it is “committed to protecting our participants and the criteria for conduct in our studies and will continue to monitor protection closely. “
Interruptions in drug trials are and the transient suspension caused a sharp drop in AstraZeneca’s percentage value after Tuesday’s announcement.
The Oxford-AstraZeneca test was already discontinued in July for several days after a player developed neurological symptoms that turned out to be an undiagnosed case of sclerosis that researchers declared unrelated to the vaccine.
During the third and final level of testing, scholars look for any symptoms of imaginable side effects that have not been detected in previous studies in patients. Because of their giant size, studies are considered the most important testing phase for detecting less common side effects and creating safety. Trials also evaluate efficacy by monitoring who is in poor health and who is not among patients receiving the vaccine and those receiving a simulated injection.
Dr. Charlotte Summers, senior professor of intensive care medicine at the University of Cambridge, said the breakup is a sign that the Oxford team prioritizes protection problems, but that it generates “a lot of unnecessary speculation. “
“To combat the global COVID-19 pandemic, we want to expand vaccines and treatments that others feel comfortable using, so it’s imperative for public confidence that we stick to evidence and don’t draw conclusions until data becomes available. She said.
Scientists and stakeholders around the world, as well as experts from the World Health Organization, have sought to involve expectations of imminent progress for coronavirus vaccines, noting that vaccine trials are rarely simple.
Italian Health Minister Roberto Speranza welcomed the resumption of the vaccine trial, but warned that caution is still necessary.
“Science is in paints to give effective remedies and vaccines globally,” he said. “In the meantime, the key remains our behavior. “
Italy, which is point 0 of the epidemic in Europe, is one of the leading countries investing in the AstraZeneca vaccine.
Two vaccines are undergoing mass last-stage testing in the United States, one manufactured through Moderna Inc. and the other through Pfizer and BioNTech in Germany.
___
Nicole Winfield contributed in Rome.
___
Track the AP pandemic in http://apnews. com/VirusOutbreak and https://apnews. com/UnderstandingtheOutbreak